Research Information System
İkinci Uluslar Arası Selçuk Sağlık Bilimleri Kongresi, Konya, Turkey, 30 November - 01 December 2023, pp.244-257, (Full Text)
Study: Cancer is one of the most prevalent diseases worldwide in our age. There are many chemotherapeutic agents currently used for the purpose of cancer treatment. Paclitaxel is one of the most useful and effective antineoplastic agents in the treatment of many forms of advanced and resistant cancers. Despite the antineoplastic effect of paclitaxel, studies have shown that paclitaxel causes ferroptosis as a side effect. Ferroptosis, known as iron-dependent cell death, is a form of necrosis associated with lipid hydroperoxide accumulation that may play a key role in the pathogenesis of degenerative diseases. Ferroptosis; it has been associated with various pathological conditions, including cancer, neurodegenerative diseases and ischemia-reperfusion injury. Ferroptosis has also been reported to cause osteoporosis. Studies have shown that ferroptosis inhibitors increase the therapeutic effectiveness of paclitaxel. Ferrostatin-1 is one of the potent inhibitors of ferroptosis. Inhibition of ferroptosis occurs by Ferrostatin-1 slowing down the accumulation of lipid hydroperoxides.
Aim: The aim of this study is to reveal the possible negative effects of paclitaxel on the tibia, to show the positive or negative effects of Ferrostatin-1 on the tibia, and to reveal whether Ferrostatin-1 administered with paclitaxel prevents the possible negative effects of paclitaxel on the tibia.
Method: In the study, 38 rats were used. Rats were divided into 4 groups: control (n:8), paclitaxel (n:10), Ferrositatin-1 (n:10) and paclitaxel + ferrocitatin-1 (n:10). Rats in the paclitaxel group were administered 10 mg/kg paclitaxel intraperitoneally. Rats in the ferrostatin-1 group were administered 5 mg/kg ferrostatin-1 intraperitoneally. Rats in the paclitaxel + ferrostatin-1 group were administered 10 mg/kg paclitaxel and 5 mg/kg ferrostatin-1 intraperitoneally. The application period continued once a week for 4 weeks. At the end of the study, the right tibia of the rats sacrificed by the cervical dislocation method was removed. The collected tibias were weighed with a precision scale and their weight (g) was determined. Additionally, the lengths (mm) and diaphyseal diameters (mm) of the tibias were measured with a digital caliper.
Results: As a result of the measurements, it was observed that there was no statistical difference in terms of tibia weight, tibia length and diaphyseal diameter in the paclitaxel, ferrostatin-1 and paclitaxel + ferrostatin-1 groups compared to the control group (P>0,05).
Conclusions: It was determined that paclitaxel did not have a negative effect on tibia weight, tibia length and diaphyseal diameter. Similarly, it was observed that ferrostatin-1 did not have a positive or negative effect on tibia weight, tibia length and diaphyseal diameter.
Keywords: Ferrostatin-1, paclitaxel, tibia.